Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes

By The Northwire Desk — AI Analysis Nov 24, 2025 · 07:05 BHC · 8.52 BAUSCH HEALTH COMPANIES INC.
BHC · Price

Executive Summary

  • Bausch Health announced a formal exchange offer to replace its outstanding 4.875% and 11.00% senior secured notes due 2028 with up to $1.6 billion of new 10.00% senior secured notes due 2032.
  • The offer includes an early‑exchange premium (additional principal) for holders tendering by Dec 8, 2025, and the exchange is structured on a target ratio of roughly 53% 11.00% notes to 47% 4.875% notes.
  • Participation agreements covering approximately $1.545 billion (≈46% of outstanding senior secured notes) have been executed, providing support for the successful completion of the transaction.

Key Details

  • Existing Notes Subject to Exchange
  • 11.00% Senior Secured Notes due 2028 – Principal outstanding: $1,774,067,000
    • Exchange consideration per $1,000 principal: $920.00
    • Early‑exchange premium: $100.00 (total consideration $1,020.00)

  • 4.875% Senior Secured Notes due 2028 – Principal outstanding: $1,600,000,000

    • Exchange consideration per $1,000 principal: $787.50
    • Early‑exchange premium: $100.00 (total consideration $887.50)

  • New Notes to be Issued

  • 10.00% Senior Secured Notes due 2032 (“New Notes”) – up to $1.6 billion aggregate principal amount.

  • Treated as a single series together with the existing $4.4 billion of 10.00% notes issued in April 2025 (Existing NumberCo Notes).

  • Offer Timeline

  • Commencement: November 24, 2025
  • Early‑exchange deadline (Early Tender Time): December 8, 2025, 5:00 PM NY time – eligible for additional premium.

  • Offer expiration: December 23, 2025 (subject to extension).

  • Target Ratio & Allocation

  • Expected acceptance ratio: 52.6% of aggregate principal from the 11.00% notes and 47.4% from the 4.875% notes.

  • Pro‑rata allocation among eligible holders, with early tenders prioritized.

  • Transaction Support Agreement

  • Approximately $1.545 billion (≈46% of total outstanding senior secured notes) pledged by participating holders to fully tender their holdings.

  • Includes covenants obligating both Offerors and Participating Holders to facilitate completion and refrain from actions that could frustrate the offer.

  • Financial Impact

  • Extends maturity profile to 2032, reducing near‑term refinancing risk.

  • Provides a net interest payment adjustment mechanism (cash settlement of accrued interest differences).

  • Eligibility & Distribution Mechanics

  • Offers limited to qualified institutional buyers or non‑U.S. persons meeting Regulation S requirements.
  • Eligible holders must certify eligibility and may obtain the Exchange Offer Memorandum via D.F. King & Co., Inc.

Notable Quotes

(No direct executive quotes were included in the release.)

Read the original news release →

More from BAUSCH HEALTH COMPANIES INC.

Jun 09, 2026 · 08:00

Canadian drug plan LOI for PrOKEDI is a steady commercial step, but the stock's -6.5% drift into the print reflects broader pipeline and debt overhangs already discounted.

Regulatory May 28, 2026 · 16:15

Solta Trademark Win Reinforces China Growth Narrative Amidst Elevated Debt Costs and Xifaxan LOE Clock

Production / Operations Apr 29, 2026 · 16:05

BHC Q1 Earnings Mask Pipeline Failure with Core Cash Flow Strength

Earnings Apr 14, 2026 · 08:00

Biafine Launch Fails to Offset Clinical Failure and Debt Burden

Other Feb 23, 2026 · 17:59

Bausch Health launches Clear + Brilliant in Canada

Regulatory Feb 23, 2026 · 08:00

Bausch Health's Aesthetics Business, Solta Medical, Announces the Launch of Clear + Brilliant(TM) Touch Laser in Canada

Production / Operations